查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1916932

胜肽-放射性核种偶联物市场按放射性核种类型、治疗适应症、给药途径、最终用户和分销管道划分 - 全球预测（2026-2032 年）

Peptide-Radionuclide Conjugates Market by Radionuclide Type, Therapeutic Indication, Route Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年肽-放射性核种偶联物市值为 9.7298 亿美元，预计到 2026 年将成长至 11.3427 亿美元，年复合成长率为 17.22%，到 2032 年将达到 29.5992 亿美元。

主要市场统计数据
基准年 2025 9.7298亿美元
预计年份：2026年 1,134,270,000 美元
预测年份：2032年 2,959,920,000 美元
复合年增长率 (%) 17.22%

权威概述了科学进步、生产要求和临床实践的融合如何重塑治疗性胜肽-放射性核素偶联物的发展。

肽-放射性核素偶联物处于靶向分子治疗和放射性药物科学不断发展的交汇点，它将肽配体与治疗性放射性核素结合，从而将局部细胞毒性辐射递送至恶性组织。连接子化学的日趋成熟、放射性核素生产技术的进步以及患者筛选标准的完善，使得这种治疗方法从一种小众研究工具转变为一种临床可行的治疗方法。随着肿瘤学向精准医疗发展，这些偶联物越来越能够针对具有特定分子标记的肿瘤类型发挥作用，为治疗选择有限的患者提供新的治疗契机。

螯合化学、生产能力、临床试验设计和治疗基础设施的创新如何加速放射性标记化合物的广泛应用

胜肽-放射性核种偶联物领域正经历一系列变革性变化，这些变化涵盖了科学突破、基础设施现代化以及不断发展的医疗服务模式。螯合化学和连接子优化的创新提高了放射性核素的稳定性和肿瘤滞留率，从而增强了治疗指数。同时，加速器和发生器型放射性核种生产能力的提升，以及放射化学自动化程度的提高，正在消除先前阻碍其广泛临床应用的操作瓶颈。

对不断变化的关税政策和贸易压力如何影响放射性标记治疗药物供应链的韧性、生产策略和临床连续性进行全面分析。

关税的征收和贸易政策的变化可能对胜肽-放射性核种偶联物价值链产生多方面的影响，到2025年，累积效应凸显了原料采购、放射性核种生产和临床供应连续性之间的相互依存关係。对前驱化学品、放射化学合成专用设备以及屏蔽运输包装组件征收的关税正在推高製造商和放射性药物配製药房的投入成本。这些成本压力促使相关人员寻求区域采购和垂直整合，以奖励其供应链免受关税波动和跨境物流延误的影响。

将放射性核种特性、临床适应症、临床环境、分发方法和给药途径与决策流程连结的深入細項分析

详细的細項分析揭示了不同放射性核种类型、治疗适应症、最终用户、分销管道和给药途径所带来的不同策略考量，这些考量共同决定了研发重点和商业化管道。在放射性核种分类中，锕-225、镏-177 和钇-90 的生产方法、放射生物学特性和供应链成熟度各不相同。每种放射性核种在处理、剂量测定和生产方面都面临着独特的挑战，这些挑战会影响临床专案设计和合作伙伴的选择。

美洲、欧洲、中东和非洲以及亚太地区的法规结构、基础设施投资和医疗服务模式将如何决定差异化的医疗服务取得和推广策略？

区域趋势将显着影响胜肽-放射性核素偶联物的开发、生产和应用。美洲、欧洲、中东和非洲以及亚太地区的法规环境、基础设施成熟度和医疗服务模式各不相同。在美洲，强大的放射性药物专业知识基础和完善的法规结构支持快速的临床转化。此外，一体化的医疗保健系统也便于病患转诊流程的协调和集中式生产的合作。迴旋加速器的资本投资趋势和发生器的可用性将继续决定该地区的医疗机构是优先考虑内部生产还是外包生产。

策略性地整合竞争定位、伙伴关係模式和製造优势，从而确立胜肽-放射性核种偶联物生态系统的主导

胜肽-放射性核种偶联物生态系统中的竞争格局由一系列参与者构成，包括专业的放射性药物研发公司、学术机构、契约製造组织以及作为上市合作伙伴的临床中心网络。产业参与者透过对放射性核种供应链的策略性投资、专有的偶联化学技术以及伴随诊断合作来提升患者选择和治疗效果，从而实现差异化竞争。原料采购、放射性标记製程和分销物流的垂直整合正逐渐成为确保供应连续性和品管的企业的竞争优势。

切实可行、影响深远的策略，旨在增强供应韧性、确保合规性、促进临床整合并实现商业性化，从而加速放射性标记化合物的治疗应用。

透过采取有针对性、可操作的策略，重点关注供应弹性、监管参与、营运准备和相关人员协调，行业领导者可以确保科学潜力转化为持续的临床和商业性成功。优先考虑放射性核素采购的冗余性，投资于区域生产能力和可靠的供应合同，可以降低贸易中断的风险，并有助于确保可靠的临床时间表。同时，投资于自动化放射化学平台和可扩展的无菌製程可以减少批次间的差异，从而实现从初始测试到广泛临床应用的平稳过渡。

严谨的多维度研究途径，结合专家访谈、技术文献综述和供应链分析，确保得出可靠且可操作的见解。

本分析的调查方法结合了多资讯来源、证据主导的方法，旨在确保研究结果的稳健性、可重复性和实用性。主要研究包括对放射化学家、核医学医师、临床实验室负责人、医院管理人员和监管事务专业人员等专家进行结构化访谈，以获取在已发表文献中未必显而易见的真实操作见解、临床工作流程的限制以及战略重点。这些定性资讯与技术文献、监管指南和已发布的临床实验室註册资讯进行交叉比对，以检验程序和科学论点。

将胜肽-放射性核素技术创新转化为持续的临床和商业性影响，需要科学、营运和政策方面的共同努力。

胜肽-放射性核素偶联物在靶向肿瘤学和放射性药物科学的交叉领域占据着重要的地位，为具有特定分子特征的肿瘤类型提供了潜在的治疗优势。此治疗方法的发展轨迹将取决于相关领域的进步：提高稳定性和肿瘤靶向性的化学技术；确保及时、品管的供应的生产和分销系统；实现精确剂量测定和安全给药的临床基础设施；以及支持循证核准的监管管道。当这些要素协调一致时，改善患者预后和开发新的治疗方案的潜力将成为现实。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依放射性核种类型分類的胜肽-放射性核种偶联物市场

  • 锕-225
  • 镏-177
  • 钇-90

9. 依治疗适应症分類的胜肽-放射性核种偶联物市场

  • 骨转移
  • 神经内分泌肿瘤
  • 摄护腺癌

10. 依给药途径分類的胜肽-放射性核种偶联物市场

  • 瘤内给药
  • 静脉注射

11. 依最终用户分類的胜肽-放射性核种偶联物市场

  • 医院
    • 综合医院
    • 专科癌症中心
  • 肿瘤中心
    • 学术中心
    • 私人诊所
  • 研究所

12. 胜肽-放射性核种偶联物市场依分销管道划分

  • 直接购买
    • 院内放射性药物分发室
    • 现场药房
  • 直接竞标
  • 经销商

13. 各地区胜肽-放射性核种偶联物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

14. 胜肽-放射性核种偶联物市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国胜肽-放射性核种偶联物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章美国胜肽-放射性核种偶联物市场

17. 中国胜肽-放射性核种偶联物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Angiochem Inc.
  • Ariceum Therapeutics
  • AstraZeneca PLC
  • Bayer AG
  • Bicycle Therapeutics Ltd.
  • Bristol Myers Squibb Company
  • Curium Pharma
  • Cybrexa Therapeutics Inc.
  • Eli Lilly and Company
  • Genentech, Inc.
  • ITM Isotope Technologies Munich SE
  • NorthStar Medical Radioisotopes LLC
  • Novartis AG
  • PeptiDream Inc.
  • Telix Pharmaceuticals Limited
Product Code: MRR-AE420CB15402

The Peptide-Radionuclide Conjugates Market was valued at USD 972.98 million in 2025 and is projected to grow to USD 1,134.27 million in 2026, with a CAGR of 17.22%, reaching USD 2,959.92 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 972.98 million
Estimated Year [2026] USD 1,134.27 million
Forecast Year [2032] USD 2,959.92 million
CAGR (%) 17.22%

An authoritative overview of how scientific advances, manufacturing requirements, and clinical practice convergence are reshaping therapeutic peptide-radionuclide conjugate development

Peptide-radionuclide conjugates represent an evolving intersection of targeted molecular therapeutics and radiopharmaceutical science, combining peptide ligands with therapeutic radionuclides to deliver localized cytotoxic radiation to malignant tissues. The maturation of linker chemistry, advances in radionuclide production technologies, and refinements in patient selection criteria have collectively transformed this modality from niche investigational tools into clinically actionable therapies. As oncology shifts toward precision approaches, these conjugates are increasingly positioned to address tumor types with defined molecular markers, offering new therapeutic windows for patients with limited options.

The development pathway for peptide-radionuclide conjugates demands coordinated progress across chemistry, radiopharmacy, clinical trial design, and regulatory engagement. Manufacturing complexities include ensuring radionuclidic purity, robust conjugation yields, and scalable synthesis workflows that meet stringent sterility and sterility-release criteria. Clinical implementation raises unique operational needs around radiation safety, dosimetry, and multidisciplinary care coordination. Consequently, stakeholders spanning biotech developers, hospital systems, specialty radiopharmacies, and regulatory bodies must align on standards that enable both rapid translation and the safeguarding of patient outcomes.

This introduction frames the subsequent analysis by emphasizing how scientific innovation, logistical infrastructure, and regulatory clarity together shape the feasibility and speed of adoption for peptide-radionuclide conjugates. With this context, readers can better appreciate the strategic levers that influence clinical uptake and commercial trajectories.

How innovations in chelation chemistry, production capacity, clinical trial design, and treatment infrastructure are collectively accelerating radioconjugate adoption

The landscape for peptide-radionuclide conjugates is being reshaped by several transformative shifts that span scientific breakthroughs, infrastructure modernization, and evolving care delivery models. Innovations in chelation chemistry and linker optimization have improved radionuclide stability and tumor retention, thereby increasing therapeutic indices. Concurrently, the expansion of accelerator and generator-based radionuclide production capabilities, together with enhanced radiochemistry automation, is reducing operational bottlenecks that historically impeded widespread clinical use.

Clinical trial design is also evolving: adaptive trial frameworks, enriched patient selection using molecular diagnostics, and integrated dosimetry endpoints are accelerating the generation of meaningful efficacy and safety data. Health systems are adapting to the operational demands of radiopharmaceutical therapies by establishing in-house radiopharmacies, onsite pharmacy workflows, and specialized treatment pathways that coordinate nuclear medicine, oncology, and radiation safety teams. Meanwhile, public and private investment in radiopharmaceutical infrastructure is incentivizing new entrants and partnerships between academic centers and industry sponsors.

These shifts interact synergistically: better chemistry enables more reliable production; improved production capacity supports broader clinical testing; and integration within care pathways increases physician familiarity and patient access. Together, they are not only expanding the therapeutic horizon for peptide-radionuclide conjugates but also creating new commercial and operational models for delivering these therapies at scale.

Comprehensive analysis of how evolving tariff policies and trade pressures have reshaped supply chain resilience, production strategy, and clinical continuity for radioconjugate therapies

The imposition of tariffs and trade policy changes can create multifaceted impacts across the peptide-radionuclide conjugate value chain, and the cumulative effects observed through 2025 underscore the interdependence of raw material sourcing, radionuclide production, and clinical supply continuity. Tariffs on precursor chemicals, specialized equipment for radiochemistry synthesis, and components used in shielded transport and packaging have raised input costs for manufacturers and radiopharmacies. These cost pressures incentivize localized sourcing and vertical integration, as stakeholders seek to insulate supply chains from tariff volatility and cross-border logistics delays.

In parallel, tariffs affecting imported generators and cyclotron parts have accelerated capital investment decisions to develop domestic production capacity or to diversify supplier relationships, particularly for critical radionuclides that cannot be stockpiled due to short half-lives. The operational response has included greater emphasis on regionalized production hubs and inter-institutional collaboration models that coordinate generator sharing and scheduled batch production to optimize utilization. Regulatory authorities and hospital administrations have had to adapt procurement policies to balance cost, compliance, and patient access implications, leading to more stringent supplier qualification and contingency planning.

Clinically, these trade dynamics have prompted healthcare providers and research centers to review scheduling protocols and inventory management strategies for patient treatments that rely on time-sensitive radionuclides. On the commercialization front, manufacturers are reevaluating pricing models, contractual terms with distributors, and invest-to-save calculations for in-house radiopharmacy capabilities. Overall, the cumulative tariff environment through 2025 has reinforced the need for resilient supply chain strategies, increased capital allocation for localized capabilities, and proactive regulatory engagement to mitigate disruptions to patient care and ongoing clinical programs.

Insightful segmentation analysis connecting radionuclide attributes, clinical indications, care settings, distribution approaches, and administration routes to strategic decision pathways

A granular view of segmentation reveals distinct strategic considerations across radionuclide type, therapeutic indication, end user, distribution channel, and route of administration that collectively inform development priorities and commercialization pathways. When categorizing by radionuclide, the landscape varies between Actinium-225, Lutetium-177, and Yttrium-90 in terms of production methods, radiobiological properties, and supply chain maturity. Each radionuclide presents unique handling, dosimetry, and manufacturing implications that influence clinical program design and partnering choices.

Therapeutic indications such as Bone Metastases, Neuroendocrine Tumors, and Prostate Cancer drive divergent clinical development strategies, with differences in patient selection criteria, imaging companion diagnostics, and dosing paradigms. End users-Hospitals, Oncology Centers, and Research Institutes-exhibit varied operational capabilities and procurement behaviors. Hospitals are further distinguished between General Hospitals and Specialized Cancer Centers, with the latter often possessing more integrated nuclear medicine services and multidisciplinary care pathways. Oncology Centers split into Academic Centers and Private Clinics, reflecting contrasts in research orientation, payer mix, and adoption risk tolerance.

Distribution channels also shape access and logistics: Direct Purchase, Direct Tender, and Distributors each entail distinct contracting dynamics and regulatory compliance responsibilities. Direct Purchase can involve InHouse Radiopharmacy or Onsite Pharmacy models, each with different capital, staffing, and regulatory footprints. Finally, the route of administration, whether Intratumoral or Intravenous, affects clinical workflow, dosing strategies, and patient management protocols. Understanding these segments in combination enables stakeholders to align product development, clinical trial design, and commercial deployment to the operational realities and unmet needs of each subgroup.

How regional regulatory frameworks, infrastructure investments, and healthcare delivery models in the Americas, Europe Middle East & Africa, and Asia-Pacific dictate differentiated strategies for deployment and access

Regional dynamics significantly influence the development, production, and adoption of peptide-radionuclide conjugates, with distinct regulatory environments, infrastructure maturity, and healthcare delivery models across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, concentrated centers of radiopharmacy expertise and established regulatory frameworks support rapid clinical translation, while the presence of integrated health systems can enable coordinated patient pathways and centralized manufacturing collaborations. Investment trends in cyclotron capacity and generator availability continue to shape how institutions in the region prioritize in-house versus outsourced production.

Across Europe, Middle East & Africa, regulatory heterogeneity and varying levels of radiopharmaceutical infrastructure present both challenges and opportunities. Some European markets demonstrate advanced adoption driven by strong nuclear medicine networks and academic-industry partnerships, whereas parts of the Middle East & Africa are focused on building foundational capabilities and regulatory alignment to support wider access. Regional initiatives to harmonize standards and to invest in centralized production hubs are increasingly relevant for cross-border supply and clinical trial collaboration.

The Asia-Pacific region shows rapid capability expansion, with substantial investments in manufacturing infrastructure, growing clinical trial activity, and rising interest from national health systems in incorporating radioconjugates into cancer care pathways. Differences in payer systems, hospital ownership models, and regulatory timelines across Asia-Pacific nations mean that entry strategies must be tailored to local reimbursement dynamics and institutional capacities. Overall, regional strategies must reflect a balance between centralized efficiency and local operational realities to support reliable patient access and program scalability.

A strategic synthesis of competitive positioning, partnership models, and manufacturing advantages that determine leadership in the peptide-radionuclide conjugate ecosystem

Competitive dynamics within the peptide-radionuclide conjugate ecosystem are shaped by a mix of specialized radiopharmaceutical developers, academic spin-outs, contract manufacturing organizations, and clinical center networks that serve as launch partners. Industry participants are differentiating through strategic investments in radionuclide supply chains, proprietary conjugation chemistries, and companion diagnostic collaborations that enhance patient selection and therapeutic outcomes. Vertical integration-spanning raw material sourcing, radiolabeling processes, and distribution logistics-has emerged as a competitive advantage for organizations seeking to ensure supply continuity and quality control.

Partnership models are also evolving: pharma and biotech entities increasingly form alliances with academic hospitals and specialty oncology centers to validate clinical protocols, while collaborations with radiopharmacy network operators help scale distribution and administration capabilities. Contract research and manufacturing providers that specialize in aseptic radiochemistry and small-batch production are gaining prominence as enabling partners for early-stage developers who lack in-house radiopharmaceutical expertise. Meanwhile, clinical centers that develop robust multidisciplinary care pathways for radioconjugates attract industry attention as preferred sites for late-stage trials and initial launches.

Intellectual property strategies focus not only on novel peptide-target combinations but also on delivery platforms, linker technologies, and dosimetry optimization methods. As the field matures, firms that can demonstrate reproducible manufacturing processes, regulatory-compliant quality systems, and effective clinical outcomes will be best positioned to capture partnership opportunities and to support sustainable commercialization.

Practical, high-impact strategies for supply resilience, regulatory alignment, clinical integration, and commercial access to accelerate adoption of radioconjugate therapies

Industry leaders can act decisively to translate scientific promise into durable clinical and commercial success by pursuing a set of targeted, actionable strategies focused on supply resilience, regulatory engagement, operational readiness, and stakeholder alignment. Prioritizing redundancy in radionuclide sourcing and investing in regional production capacity or secured supply agreements reduces vulnerability to trade disruptions and supports reliable clinical scheduling. Simultaneously, investing in automated radiochemistry platforms and scalable aseptic processes can lower per-batch variability and enable smoother transitions from early trials to broader clinical use.

Proactive regulatory engagement is essential: leaders should initiate early dialogue with regulatory bodies to clarify expectations around quality attributes, dosimetry endpoints, and trial designs that balance safety with meaningful efficacy signals. Establishing formal collaborations with leading clinical centers, oncology networks, and radiopharmacy operators accelerates protocol optimization, patient recruitment, and real-world evidence generation. On the commercial side, aligning reimbursement strategies with health economic evidence and patient-centered outcomes will facilitate payer discussions and market access planning.

Operationally, building multidisciplinary treatment pathways that integrate nuclear medicine, medical oncology, radiation safety, and pharmacy services will improve patient throughput and experience. Finally, corporate strategy should include transparent IP frameworks, flexible distribution models that accommodate both centralized and onsite radiopharmacy approaches, and investments in training and education programs to build clinician familiarity and confidence in these therapies. Taken together, these actions create a comprehensive playbook for converting technological advantages into patient impact and sustainable enterprise value.

A rigorous, multi-method research approach combining expert interviews, technical literature synthesis, and supply chain analysis to ensure robust and actionable insights

The research methodology underpinning this analysis combined a multi-source, evidence-driven approach designed to ensure robustness, reproducibility, and practical relevance. Primary research included structured interviews with subject-matter experts such as radiochemists, nuclear medicine physicians, clinical trialists, hospital administrators, and regulatory affairs specialists to capture real-world operational insights, clinical workflow constraints, and strategic priorities that are not always visible in public literature. These qualitative inputs were triangulated against technical literature, regulatory guidances, and publicly available clinical trial registries to validate procedural and scientific assertions.

Secondary research drew on peer-reviewed journals, technical conference proceedings, manufacturer publications, and regulatory documents to establish factual baselines for radionuclide properties, manufacturing requirements, and safety considerations. Supply chain analysis incorporated trade datasets, manufacturing equipment specifications, and capital investment trends to assess production capacity and logistical constraints. Where quantitative data were used for comparative analyses, sources were selected for credibility and recency, and assumptions were documented to maintain transparency.

Analytical frameworks emphasized cross-validation, whereby findings from one method informed probes in another, reducing single-source bias. Limitations include the inherent variability of rapidly evolving clinical evidence and the sensitivity of proprietary commercial contract terms that are not always publicly disclosed. To mitigate these constraints, iterative expert validation and sensitivity analyses were applied to ensure the findings remain actionable and grounded in current practice.

Convergent scientific, operational, and policy actions are required to translate peptide-radionuclide innovations into lasting clinical and commercial impact

Peptide-radionuclide conjugates occupy a critical niche at the intersection of targeted oncology and radiopharmaceutical science, offering potential therapeutic advantages for tumor types with specific molecular characteristics. The trajectory of this modality is determined by progress across complementary domains: chemistry that improves stability and tumor targeting, manufacturing and distribution systems that assure timely and quality-controlled supply, clinical infrastructures that enable precise dosimetry and safe administration, and regulatory pathways that support evidence-driven approvals. When these elements align, the potential for improved patient outcomes and new therapeutic options becomes tangible.

However, realizing this potential requires sustained attention to operational detail and strategic foresight. Supply chain vulnerabilities, trade policy dynamics, and the capital intensity of radiopharmacy infrastructure can slow clinical access if not proactively managed. Equally important are the collaborative networks that link developers, clinical centers, regulators, and payers; these partnerships are critical for designing trials that demonstrate meaningful benefit, for establishing care pathways that enable scalable adoption, and for securing reimbursement frameworks that reflect clinical value.

In conclusion, the future of peptide-radionuclide conjugates is promising but contingent on coordinated action across scientific, operational, and policy domains. Stakeholders who invest in resilient supply strategies, clear regulatory dialogue, and integrated clinical models will be best positioned to translate innovation into sustainable patient impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Peptide-Radionuclide Conjugates Market, by Radionuclide Type

  • 8.1. Actinium-225
  • 8.2. Lutetium-177
  • 8.3. Yttrium-90

9. Peptide-Radionuclide Conjugates Market, by Therapeutic Indication

  • 9.1. Bone Metastases
  • 9.2. Neuroendocrine Tumors
  • 9.3. Prostate Cancer

10. Peptide-Radionuclide Conjugates Market, by Route Administration

  • 10.1. Intratumoral
  • 10.2. Intravenous

11. Peptide-Radionuclide Conjugates Market, by End User

  • 11.1. Hospitals
    • 11.1.1. General Hospitals
    • 11.1.2. Specialized Cancer Centers
  • 11.2. Oncology Centers
    • 11.2.1. Academic Centers
    • 11.2.2. Private Clinics
  • 11.3. Research Institutes

12. Peptide-Radionuclide Conjugates Market, by Distribution Channel

  • 12.1. Direct Purchase
    • 12.1.1. InHouse Radiopharmacy
    • 12.1.2. Onsite Pharmacy
  • 12.2. Direct Tender
  • 12.3. Distributors

13. Peptide-Radionuclide Conjugates Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Peptide-Radionuclide Conjugates Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Peptide-Radionuclide Conjugates Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Peptide-Radionuclide Conjugates Market

17. China Peptide-Radionuclide Conjugates Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Angiochem Inc.
  • 18.6. Ariceum Therapeutics
  • 18.7. AstraZeneca PLC
  • 18.8. Bayer AG
  • 18.9. Bicycle Therapeutics Ltd.
  • 18.10. Bristol Myers Squibb Company
  • 18.11. Curium Pharma
  • 18.12. Cybrexa Therapeutics Inc.
  • 18.13. Eli Lilly and Company
  • 18.14. Genentech, Inc.
  • 18.15. ITM Isotope Technologies Munich SE
  • 18.16. NorthStar Medical Radioisotopes LLC
  • 18.17. Novartis AG
  • 18.18. PeptiDream Inc.
  • 18.19. Telix Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ACTINIUM-225, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ACTINIUM-225, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ACTINIUM-225, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY LUTETIUM-177, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY LUTETIUM-177, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY LUTETIUM-177, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY YTTRIUM-90, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY YTTRIUM-90, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY YTTRIUM-90, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY BONE METASTASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY BONE METASTASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY BONE METASTASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY GENERAL HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY GENERAL HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY SPECIALIZED CANCER CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY SPECIALIZED CANCER CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY SPECIALIZED CANCER CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ONCOLOGY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ONCOLOGY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ONCOLOGY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ACADEMIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ACADEMIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ACADEMIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY INHOUSE RADIOPHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY INHOUSE RADIOPHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY INHOUSE RADIOPHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ONSITE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ONSITE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ONSITE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ONCOLOGY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ONCOLOGY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ONCOLOGY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ONCOLOGY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ONCOLOGY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ONCOLOGY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ONCOLOGY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ONCOLOGY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ONCOLOGY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 156. GCC PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. GCC PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GCC PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 159. GCC PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ONCOLOGY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 160. GCC PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. GCC PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ONCOLOGY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ONCOLOGY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, 2018-2032 (USD MILLION)
  • TABLE 180. G7 PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. G7 PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. G7 PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. G7 PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. G7 PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ONCOLOGY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 187. G7 PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. G7 PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, 2018-2032 (USD MILLION)
  • TABLE 189. NATO PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. NATO PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. NATO PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 192. NATO PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. NATO PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. NATO PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 195. NATO PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ONCOLOGY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 196. NATO PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. NATO PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ONCOLOGY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY ONCOLOGY CENTERS, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA PEPTIDE-RADIONUCLIDE CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, 2018-2032 (USD MILLION)